Drug Profile
NAI Acne - NAICONS
Alternative Names: BI-Acne; BI-K-0376; CB-06-01; CB-06-04; NAI-003; NAI-Acne; VIC-acneLatest Information Update: 07 Sep 2021
Price :
$50
*
At a glance
- Originator Vicuron Pharmaceuticals
- Developer Cassiopea; NAICONS
- Class Amides; Antiacnes; Antibacterials; Peptide antibiotics; Peptides
- Mechanism of Action Peptide elongation factor Tu inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acne vulgaris
Most Recent Events
- 07 Sep 2021 NAI Acne is still in phase II trials for Acne vulgaris in Slovakia (Cassiopea pipeline, September 2021) (NAICONS' pipeline, September 2021)
- 11 Mar 2019 NAI Acne is still in phase II trials for Acne vulgaris in Slovakia (Cassiopea website, March 2019)
- 11 Mar 2019 Cassiopea plans a phase III trial for Acne Vulgaris in 2021-2022 (Topical) (Cassiopea pipeline, March 2019)